Currently out of the existing stock ratings of Alec Stranahan, 11 are a BUY (47.83%), 5 are a HOLD (21.74%), 7 are a SELL (30.43%).

Alec Stranahan

Work Performance Price Targets & Ratings Chart

Analyst Alec Stranahan works at BAML with a stock forecast success ratio of 57.44% fulfilled within 137.63 days on average.

Alec Stranahan’s has documented 46 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RVMD, Revolution Medicines at 05-Jan-2024.

Wall Street Analyst Alec Stranahan

Analyst best performing recommendations are on YMAB (Y MABS THERAPEUTICS).
The best stock recommendation documented was for TGTX (TG THERAPEUTICS) at 5/20/2022. The price target of $5 was fulfilled within 4 days with a profit of $0.39 (7.24%) receiving and performance score of 18.09.

Average potential price target upside

NXTC NextCure  KRYS Krystal Biotech NVAX Novavax TGTX TG Therapeutics YMAB Y mAbs Therapeutics DAWN Day One Biopharmaceuticals RVMD Revolution Medicines MGTX MeiraGTx Holdings PLC

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

4

$2.06 (106.19%)

6

3 months 14 days ago

0/5 (0%)

$2.83 (241.88%)

Hold

16

1 years 4 months 24 days ago

0/3 (0%)

$11.08 (225.20%)

Buy

6

$4.06 (209.28%)

13

1 years 4 months 25 days ago

3/14 (21.43%)

$3.49 (139.04%)

56

Buy

15

$13.06 (673.20%)

19

1 years 7 months 5 days ago

1/4 (25%)

$10.56 (237.84%)

185

Buy

14

$12.06 (621.65%)

14

1 years 10 months 22 days ago

0/3 (0%)

$10.2 (268.42%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Alec Stranahan is most bullish on?

Potential upside of $12.79 has been obtained for MGTX (MEIRAGTX HOLDINGS PLC)

Which stock is Alec Stranahan is most reserved on?

Potential downside of -$6.5 has been obtained for YMAB (Y MABS THERAPEUTICS)

What Year was the first public recommendation made by Alec Stranahan?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?